TG Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.07 | -$0.05 | -$0.06 |
| Q2 2024 | 3 | -$0.05 | -$0.04 | -$0.05 |
| Q3 2024 | 5 | $0.02 | $0.06 | $0.03 |
| Q4 2024 | 8 | $0.02 | $0.14 | $0.09 |
| Q1 2025 | 4 | $0.07 | $0.18 | $0.12 |
| Q2 2025 | 2 | $0.18 | $0.22 | $0.20 |
| Q3 2025 | 2 | $0.22 | $0.27 | $0.24 |
| Q4 2025 | 2 | $0.31 | $0.38 | $0.34 |
TG Therapeutics, Inc. Earnings Date And Information
TG Therapeutics, Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The company had revenue of 73.47 M for the quarter and had revenue of 233.66 M for the year. TG Therapeutics, Inc. has generated $0 earnings per share over the last year ($0.0853 diluted earnings per share) and currently has a price-to-earnings ratio of 39.11. TG Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based on prior year's report dates.
TG Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/09/2024 | Q2 2024 | $0.05 | $65.92 M | $73.47 M | ||
| 05/06/2024 | Q1 2024 | -$0.07 | $63.47 M | |||
| 08/09/2024 | Q4 2023 | -$0.10 | $43.97 M | |||
| 11/06/2023 | Q3 2023 | $0.80 | $23.91 M | $165.82 M | ||
| 08/04/2023 | Q2 2023 | -$0.34 | $17.39 M | $16.07 M | ||
| 05/08/2023 | Q1 2023 | -$0.28 | $7.80 M | |||
| 03/01/2023 | Q4 2022 | -$0.39 | $80,000 | |||
| 11/09/2022 | Q3 2022 | -$0.27 | $1.46 M | $94,000 | ||
| 08/09/2022 | Q2 2022 | -$0.31 | $175,429 | $594,000 | ||
| 05/10/2022 | Q1 2022 | -$0.55 | -$0.53 | 0.02 | $2.02 M | |
| 03/01/2022 | Q4 2021 | -$0.62 | -$0.70 | -0.08 | $2.32 M | |
| 11/08/2021 | Q3 2021 | -$0.65 | $2.97 M | $2.03 M | ||
| 08/06/2021 | Q2 2021 | -$0.59 | $3.61 M | $1.55 M | ||
| 05/10/2021 | Q1 2021 | -$0.52 | -$0.69 | -0.17 | $793,000 | |
| 03/01/2021 | Q4 2020 | -$0.71 | $38,000 | |||
| 11/09/2020 | Q3 2020 | -$0.41 | -$0.73 | -0.32 | $19,000 | $38,000 |
| 08/10/2020 | Q2 2020 | -$0.32 | -$0.47 | -0.15 | $22,800 | $38,000 |
| 05/11/2020 | Q1 2020 | -$0.37 | -$0.48 | -0.11 | $38,000 | |
| 03/02/2020 | Q4 2019 | -$0.41 | $38,000 | |||
| 11/12/2019 | Q3 2019 | -$0.36 | -$0.69 | -0.33 | $34,500 | $38,000 |
TG Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is TG Therapeutics, Inc.'s earnings date?
TG Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates.
-
How can I listen to TG Therapeutics, Inc.'s earnings conference call?
The conference call for TG Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read TG Therapeutics, Inc.'s conference call transcript?
The conference call transcript for TG Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does TG Therapeutics, Inc. generate each year?
TG Therapeutics, Inc. (:TGTX) has a recorded annual revenue of $233.66 M.
-
How much profit does TG Therapeutics, Inc. generate each year?
TG Therapeutics, Inc. (:TGTX) has a recorded net income of $233.66 M. TG Therapeutics, Inc. has generated $0.0893 earnings per share over the last four quarters.
-
What is TG Therapeutics, Inc.'s price-to-earnings ratio?
TG Therapeutics, Inc. (:TGTX) has a price-to-earnings ratio of 39.11 and price/earnings-to-growth ratio is 0.3.
